Goal
Sleep
The peptides readers look up for sleep, and whether each can be prescribed or compounded in the U.S. today. Every status below names the FDA document it rests on.
Prescribable now
A short copy of the hormone that tells the pituitary to release growth hormone. Small 1990s studies show it raises growth hormone; none tested it against placebo for aging, body composition or sleep. Read the Sermorelin guide
Component of an FDA-approved drug (GEREF, sermorelin acetate). FDA determined in 2013 that GEREF was not withdrawn from sale for reasons of safety or effectiveness.
Source:FDA document, read September 2026.
Sellers for sleep
The licensed telehealths we have reviewed that prescribe Sermorelin for sleep. Each links to the seller and to our review of it.
Disclosure: This Peptide is reader-supported. No link on this site earns a commission today, so nothing here is a paid placement. How we make money.
- Breeze MedsPrescribesSermorelin
- CoreAge RxPrescribesSermorelin
- Strut HealthPrescribesSermorelin
- Synergy RxPrescribesSermorelin
Ordered by how many of these peptides each seller prescribes, then by name. A partnership never changes the order.
Research on sleep
- CJC 1295 and Ipamorelin: What Human Studies Exist for the PairEach peptide has a thin human record of its own. No trial of the two taken together has been published or registered, and FDA has flagged safety concerns about both.
- Does Sermorelin Work? What the Human Studies MeasuredSmall studies in older men show sermorelin raises growth hormone, and at twice-daily doses IGF-1. No placebo-controlled trial has shown it changes muscle, fat or sleep in adults.
- DSIP Peptide: What Delta Sleep-Inducing Peptide Trials in People FoundOne small double-blind study found better sleep; two others found effects too weak to matter. All used IV doses. The FDA calls the evidence inconclusive, and DSIP is research-only.
- Growth Hormone Peptides: GHRH Analogs vs Ghrelin Mimetics, and Their EvidenceEvery growth hormone peptide works through one of two receptors. Only one holds a current FDA approval, and the FDA flags several of the rest for safety risks.
- Ipamorelin: What the Human Evidence Actually ShowsOne dosing study in healthy men and one bowel-surgery trial that missed its goal. That is the published human record for a peptide sold for muscle, fat loss and sleep.
- Ipamorelin Side Effects: What the Few Human Trials RecordedTwo small human studies, both by vein, make up the record. The FDA flags serious events with intravenous use, and nobody has measured the injection people actually buy.
- Peptides for Sleep: What Human Studies of GHRH and DSIP FoundGHRH deepened sleep in young men, worsened it in young women and did less in older adults. DSIP, the peptide named for sleep, showed little benefit in insomnia.
- Sermorelin Before and After: What Trials Measured Over Weeks and MonthsThe sermorelin studies published no photos. Here is what the studies did measure at 2 weeks, 6 weeks, 16 weeks and a year, and which changes never showed up.
- Sermorelin Dosage: What the Approved Product and Trials Actually UsedA single diagnostic dose, a nightly pediatric regimen, and two small studies in older men. That is the whole documented record for sermorelin dosing.
- Sermorelin Nasal Spray: Does GHRH Work Without an Injection?The only approved sermorelin was an injection. Nasal studies of the same molecule found 3–5% reached the blood, and no study has tested it by mouth or as a troche.
- Sermorelin Side Effects: What the Trials and FDA Record ReportFlushing and injection-site pain are the reported side effects. The harder truth is how small the safety record is, especially for the adults who use it today.
- Sermorelin vs Ipamorelin: Two Very Different Evidence RecordsNo head-to-head trial turns up in PubMed. One was an approved drug with a year-long pediatric trial; the other has a dosing study and a trial that missed its goal.
- Tesamorelin vs Sermorelin: Two GHRH Analogs With Very Different EvidenceBoth copy the hormone that tells the pituitary to release growth hormone. One has FDA-approved trials in more than 800 people; the other has two small studies in older men.